believe will supplement the information otherwise 
available to 
you. We will also attempt to answer questions that you may have 
and to assist you in identifying areas of questions and dialogue 
that can benefit from the continued association of our two 
groups. We hope that this dialogue will contribute to an 
enhancement of public acceptance of the biotechnology industry 
and the regulatory climate in which we operate. To that end I 
will discuss our members' practices in general terms in several 
particular areas of biotechnology commercialization. 
Compliance with the NIH Guidelines has become accepted 
industry practice. In addition the industry has complied with 
the extensive other regulations to which it is subject. The 
present government regulations governing our work other than the 
NIH Guidelines are already comprehensive ( e . g . , those of the EPA , 
OSHA, FDA, U.S.D.A.), yet we believe that we can work under these 
regulations and safely produce effective products. Additional 
regulation would contribute little to public health and safety 
and would be duplicative and cumbersome from industry's point of 
view. Accordingly, we believe that the present regulatory 
balance has been properly struck between the public and industry, 
and should not be altered significantly. 
1 . Current Industry Practice . 
One of the areas in which we think we could be most 
helpful to you is informing you as to current industry practices 
in the area of biotechnology. The industry is beginning to make 
- 2 - 
[531] 
